Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rejuva System Device and RJVA-001 in adults with uncontrolled type 2 diabetes
NL-OMON58607Not yet recruiting
- Sponsor
- Fractyl Health
- Start
- Jun 2026
- Modality
- Small Molecules, AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of Rejuva and sirolimus in type 2 diabetes mellitus (T2DM), sponsored by Fractyl Health. Primary endpoint: Safety and tolerability of RJVA-001 delivered using the Rejuva Device System. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
Rejuvasirolimus
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON58607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58607.